Mettler-Toledo International (MTD) Bank of America 2025 Healthcare Conference summary

Business performance highlights

• Achieved 3% underlying growth in Q1, with lab business growing mid-single digits and process analytics up nearly 10%.

• Product inspection grew 8%, supported by new product introductions and strong operational execution.

• Margins exceeded expectations due to successful margin initiatives and operational improvements.

• Liquid handling and pipette businesses experienced softness, particularly in small biotech and academia segments.

• Bioprocessing and process analytics showed strong performance, especially in single-use technologies.

Fiscal year 2025 guidance and tariff impacts

• Adjusted top-line guidance to reflect trade war uncertainty and direct tariff costs, expecting a flattish volume trend for the year.

• EPS guidance reduced by 2–2.5%, with tariffs contributing a 2% headwind after mitigation efforts.

• Gross tariff impact estimated at 7% of EPS, with mitigation through supply chain optimization, cost savings, and pricing actions.

• Recent China tariff de-escalation expected to reduce gross headwind by about 3.5% of EPS for the year.

• Pricing surcharges are being adjusted dynamically in response to tariff changes.

Regional and end-market trends

• China guidance revised from low single-digit growth to a slight decline for the year, reflecting ongoing uncertainty.

• Positive outlook for China if trade de-escalation and potential government stimulus materialize.

• Strong alignment with Chinese government priorities in life sciences, food, and specialty chemicals.

• Emerging markets outside China now represent a larger share of business and are growing well, benefiting from supply chain diversification.

• Core industrial business expected to be flat for the year, with softness in chemicals and higher China exposure.